{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:13:19Z","timestamp":1793851999296,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"J&J Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ahj.2025.02.011","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:31:10Z","timestamp":1740076270000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)"],"prefix":"10.1016","volume":"285","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-9125","authenticated-orcid":false,"given":"C. Michael","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cecilia","family":"Bahit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha Al","family":"Lamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Horrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot S.","family":"Barnathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei N.","family":"Plotnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiaowei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.02.011_bib0001","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0002","first-page":"35","article-title":"The evolution of coronary stents: a brief review","volume":"30","author":"Simard","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2016.03.003","article-title":"Targeting thrombin long-term after an acute coronary syndrome: opportunities and challenges","volume":"81","author":"De Caterina","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0004","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","article-title":"Coagulation activation and long-term outcome in acute coronary syndromes","volume":"102","author":"Ardissino","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2025.02.011_bib0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1160\/th14-03-0265","article-title":"Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome","volume":"112","author":"Weitz","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2025.02.011_bib0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.02.011_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0008","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0009","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158355","article-title":"Factor XIa and thrombin generation are elevated in patients with acute coronary syndrome and predict recurrent cardiovascular events","volume":"11","author":"Loeffen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2025.02.011_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC Review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0012","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0013","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2025.02.011_bib0014","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.ahj.2025.02.011_bib0015","unstructured":"ClinicalTrials.gov. A study of milvexian in participants after a recent acute coronary syndrome. https:\/\/ClinicalTrials.gov\/show\/NCT05754957. Updated July 17, 2024. Accessed August 8, 2024."},{"key":"10.1016\/j.ahj.2025.02.011_bib0016","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"9,Suppl A)","key":"10.1016\/j.ahj.2025.02.011_bib0017","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0735-1097(22)01626-6","article-title":"Ticagrelor monotherapy after PCI across the spectrum of high-risk patients: a deep dive into the TWILIGHT Trial","volume":"29","author":"Nicolas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0018","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ahj.2025.02.011_bib0020","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.02.011_bib0021","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/10543406.2014.932285","article-title":"Alternative views on setting clinical trial futility criteria","volume":"24","author":"Gallo","year":"2014","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.ahj.2025.02.011_bib0022","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/sim.3538","article-title":"Adaptive designs for confirmatory clinical trials","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11936-010-0075-8","article-title":"Thrombi of different pathologies: implications for diagnosis and treatment","volume":"12","author":"Santos-Gallego","year":"2010","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0024","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.02.011_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0026","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.thromres.2024.02.003","article-title":"Thrombin as target for prevention of recurrent events after acute coronary syndromes","volume":"235","author":"Bahit","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2025.02.011_bib0027","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.02.011_bib0028","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","author":"Piccini","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.02.011_bib0029","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2025.02.011_bib0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: the Librexia atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:59:12Z","timestamp":1762077552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"alternative-id":["S0002870325000444"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.02.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}